MedTrace Logo

Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome.

NCT03723811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2022-04-07

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of SJP002 ophthalmic solution compared to placebo in patients with Dry Eye Syndrome.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

SJP002 BID

1 drop b.i.d for 12 weeks

DRUG

SJP002 QID

1 drop q.i.d for 12 weeks

DRUG

SJP002 Placebo 1

1 drop q.i.d for 12 weeks

DRUG

SJP002 Placebo 2

1 drop q.i.d for 12 weeks

Sponsors & Collaborators

  • Samjin Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Choun-Ki Joo, M.D.,Ph.D. · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2018-06-26
Completion
2018-06-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03723811 on ClinicalTrials.gov